$CYDY News

CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026

CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO

CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer

CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript

CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026

CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer

CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th

CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab

CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease

CytoDyn to Present at the LD Micro Invitational XVI

CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript

CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer

CytoDyn to Host Investor Webcast

CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026

CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026

CytoDyn to Present at the AACR Annual Meeting 2026

CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer

CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab

Creatv Bio's LifeTracDx® Blood Test Utilized as Exploratory Biomarker in CytoDyn's Phase 2 Study in Patients with Relapsed/Refractory Metastatic Colorectal Cancer